Sweden
· Delayed Price · Currency is SEK STO: EXPRS2 Statistics
Total Valuation
ExpreS2ion Biotech Holding AB has a market cap or net worth of SEK 43.27 million. The enterprise value is -31.24 million.
| Market Cap | 43.27M |
| Enterprise Value | -31.24M |
Important Dates
The next estimated earnings date is Thursday, February 6, 2025.
| Earnings Date | Feb 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ExpreS2ion Biotech Holding AB has 2.10 million shares outstanding. The number of shares has increased by 36.62% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 2.10M |
| Shares Change (YoY) | +36.62% |
| Shares Change (QoQ) | -46.68% |
| Owned by Insiders (%) | 0.66% |
| Owned by Institutions (%) | 11.36% |
| Float | 2.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.79 |
| PB Ratio | 0.62 |
| P/TBV Ratio | 0.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.92 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.71 |
Financial Position
The company has a current ratio of 2.85, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.85 |
| Quick Ratio | 2.83 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.04 |
| Interest Coverage | -88.16 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 440,611 |
| Profits Per Employee | -1.89M |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.36% in the last 52 weeks. The beta is 1.61, so ExpreS2ion Biotech Holding AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | -75.36% |
| 50-Day Moving Average | 25.24 |
| 200-Day Moving Average | 48.02 |
| Relative Strength Index (RSI) | 43.55 |
| Average Volume (20 Days) | 26,034 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ExpreS2ion Biotech Holding AB had revenue of SEK 7.93 million and -34.01 million in losses. Loss per share was -23.33.
| Revenue | 7.93M |
| Gross Profit | 3.86M |
| Operating Income | -68.59M |
| Pretax Income | -39.94M |
| Net Income | -34.01M |
| EBITDA | -66.94M |
| EBIT | -68.59M |
| Loss Per Share | -23.33 |
Balance Sheet
The company has 76.40 million in cash and 1.90 million in debt, giving a net cash position of 74.50 million or 35.47 per share.
| Cash & Cash Equivalents | 76.40M |
| Total Debt | 1.90M |
| Net Cash | 74.50M |
| Net Cash Per Share | 35.47 |
| Equity (Book Value) | 69.35M |
| Book Value Per Share | 33.02 |
| Working Capital | 61.55M |
Cash Flow
In the last 12 months, operating cash flow was -43.41 million and capital expenditures -888,000, giving a free cash flow of -44.30 million.
| Operating Cash Flow | -43.41M |
| Capital Expenditures | -888,000 |
| Free Cash Flow | -44.30M |
| FCF Per Share | -21.09 |
Margins
| Gross Margin | 48.66% |
| Operating Margin | -864.86% |
| Pretax Margin | -503.54% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ExpreS2ion Biotech Holding AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -36.62% |
| Shareholder Yield | -36.62% |
| Earnings Yield | -113.25% |
| FCF Yield | -102.38% |
Stock Splits
The last stock split was on October 30, 2024. It was a reverse split with a ratio of 0.025.
| Last Split Date | Oct 30, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.025 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |